Search peptides, terms, sources/
Growth hormone axis

CJC-1295

Also known as: CJC-1295 with DAC

Long-acting growth-hormone-releasing hormone analogue studied for hormone levels in healthy adults. Not licensed in the UK; human evidence is small, short trials.

UK status checked . Evidence last reviewed . By the PeptGuru editorial team (Astute Management).

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Limited evidence (level 2 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

2 findings at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. CJC-1295 is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human trials2 human trials

What is CJC-1295?

CJC-1295 is a synthetic long-acting analogue of growth-hormone-releasing hormone, studied for its effect on growth hormone and IGF-1 levels. It is not licensed in the UK, and the human evidence cited is two small, short trials in healthy adults that measured hormone levels, not clinical outcomes.

It carries a Drug Affinity Complex (DAC) that binds albumin in the blood after injection. This is designed to make it last longer in the body.

Class
GHRH analogue (long-acting, DAC-modified)
Origin
Analogue / modified
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does CJC-1295 work?

CJC-1295 is a version of growth-hormone-releasing hormone with an added chemical group that binds albumin, a protein in blood. This makes it last days instead of minutes. It binds the pituitary receptor and raises growth hormone and IGF-1. Only small, short trials in healthy adults have measured this.

The mechanism in more detail

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH) that binds the GHRH receptor on pituitary somatotroph cells, activating a signalling pathway that increases growth hormone synthesis and release. Its defining feature is the Drug Affinity Complex (DAC) modification, which allows the molecule to covalently bind circulating albumin after injection. This is reported to extend its plasma half-life from the few minutes typical of native GHRH to approximately six to eight days.

In two dose-escalation trials in healthy adults, reported in one paper, a single dose of CJC-1295 with DAC produced dose-dependent rises in growth hormone of two- to ten-fold above baseline for six days or more, and in IGF-1 of one-and-a-half to three-fold above baseline lasting nine to eleven days; after two or three repeated doses, IGF-1 stayed above baseline for up to 28 days. This is the only human trial report cited on this page; it measured hormone levels rather than a clinical outcome, and has not been independently replicated.

Classification and structure

Names
CJC-1295; CJC-1295 with DAC (Drug Affinity Complex)
Class
GHRH analogue (long-acting, DAC-modified)
Origin
Analogue / modified
Routes used in the research
Subcutaneous injection in the human trials in healthy adults. This reflects study methodology, not a usage instruction.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

CJC-1295 has 2 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

2 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
02000

Growth hormone and IGF-1 elevation Limited

In two randomised, double-blind, placebo-controlled, ascending-dose trials in healthy adults (age 21 to 61), lasting 28 and 49 days, the first gave one of four ascending single doses and the second gave 2 or 3 weekly or biweekly doses of subcutaneous CJC-1295 with DAC. After a single injection, mean growth hormone rose 2- to 10-fold for 6 days or more and mean IGF-1 rose 1.5- to 3-fold for 9 to 11 days, rising with dose. After multiple doses, mean IGF-1 stayed above baseline for up to 28 days.

Study type
Human trial
Population
Human, healthy adults aged 21-61, two randomised placebo-controlled ascending-dose trials (ascending single doses in the first; 2 or 3 weekly or biweekly doses in the second)
Source
1 Teichman et al., 2006

Limitation: Two short trials (28 and 49 days) of single or a few repeated doses, not chronic dosing.

Limitations in full

Two short trials (28 and 49 days) of single or a few repeated doses, not chronic dosing. Randomised and placebo-controlled, but not independently replicated, and no chronic-dosing efficacy trial was identified. This is the only human trial report cited on this page, and it measures hormone levels rather than a clinical outcome. Evidence strength is rated Limited.

Adverse events in the first trial Limited

In the first trial, as summarised in a 2024 FDA briefing, adverse events were reported in 33 of 35 people given CJC-1295 with DAC and in 2 of 7 given placebo. About 70% of those given the drug had injection-site reactions. Headache (63%, against 14% on placebo), diarrhoea (43%) and flushing, warmth or a short drop in blood pressure (30%) were also reported, more often at higher doses. The authors stated that no significant antibody formation was detected.

Study type
Human trial
Population
Human, healthy adults, first of the two trials in Finding 1 (35 given CJC-1295 with DAC, 7 placebo)
Source
2 FDA, 2024

Limitation: One short trial in healthy volunteers, mostly single doses.

Limitations in full

One short trial in healthy volunteers, mostly single doses. The figures are the FDA's summary of the published paper, whose full text we did not read. The FDA notes that the antibody result does not rule out antibody formation with longer, repeated use.

What safety findings have been reported?

1 safety finding is recorded for CJC-1295. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Adverse-reaction reporting

An FDA advisory-committee briefing (December 2024) summarises two small trials in healthy adults aged 21 to 61. In the first, side effects were reported in 33 of 35 people given CJC-1295 with DAC and in 2 of 7 given placebo. About 70% of those given the drug had injection-site reactions. Headache, diarrhoea and flushing with a short drop in blood pressure were also reported, more often at higher doses. The trial authors reported no serious adverse reactions. Separately, the same FDA briefing says, relying on internet reports because the data were not published, that the developer stopped clinical development in 2006 after a participant in a later phase 2 trial died, and that the participant was reported to have had undiagnosed coronary artery disease. We found no published account of that trial or of the cause of death. This page does not say that CJC-1295 caused the death, or that it did not. Trials this small cannot rule out rarer harms, and 28 to 49 days in healthy volunteers says nothing about longer use.

Source
2 FDA, 2024

What is CJC-1295's UK regulatory status?

Marketing authorisation
No UK marketing authorisation found. Not a licensed medicine. A check of the MHRA Products database active substance index on 14 November 2026 found no entry for CJC-1295.
Prescription status
Not applicable, no licensed UK product was found to classify. If licensed, growth hormone secretagogue and GHRH analogues of this type would be expected by default to be classified as prescription-only medicines, an inference, not a confirmed MHRA statement.
Medicine class
Not classified as a licensed medicine; treated by the MHRA as unlicensed where sold or supplied with medicinal claims.
MHRA position
No CJC-1295-specific MHRA enforcement notice, Yellow Card FOI data, or public assessment report was located. Unlicensed supply for human use is unlawful under the Human Medicines Regulations 2012.
Authorised use
None.
Other restrictions
The US FDA lists CJC-1295 among compounding nominations it has flagged for immunogenicity risk and reported adverse events, including increased heart rate. This is not a UK regulatory position. In sport, the WADA 2026 Prohibited List (in force from 1 January 2026) names CJC-1295 under S2.2.4, growth hormone-releasing hormone analogues.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. CJC-1295 is recorded as not licensed in the UK (checked 14 November 2026).

References

3 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. The Journal of Clinical Endocrinology & MetabolismHuman clinical trial, RCT · DOI 10.1210/jc.2005-1536 · PMID 16352683 · Original ↗
  2. US Food and Drug Administration (2024). FDA Briefing Document, Pharmacy Compounding Advisory Committee: CJC-1295-Related Bulk Drug Substances. Pharmacy Compounding Advisory Committee, meeting of 4 December 2024Regulatory / legislative document · Original ↗
  3. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about CJC-1295

What is CJC-1295?

CJC-1295 is a synthetic long-acting analogue of growth-hormone-releasing hormone, studied for its effect on growth hormone and IGF-1 levels. It is not licensed in the UK, and the human evidence cited is two small, short trials in healthy adults that measured hormone levels, not clinical outcomes. Read what it is.

Is CJC-1295 licensed in the UK?

PeptGuru records CJC-1295's UK status as: Not licensed in the UK. No UK marketing authorisation found. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on CJC-1295 show?

PeptGuru records 2 research findings for CJC-1295: 2 from human trials. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for CJC-1295?

1 safety finding is recorded, including: adverse-reaction reporting. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for CJC-1295?

All 3 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Regulatory update · UK status now cites a dated MHRA database check. WADA 2026 listing added (S2.2.4).

How findings are graded: the grading method. All changes.

  • TesamorelinTH9507

    Not licensed in the UK. Growth-hormone-releasing hormone analogue studied for visceral fat in HIV-associated lipodystrophy, in randomised trials.

    Growth hormone axisHuman trialsEvidence reviewed
    StrongNot licensed in the UK
  • AOD-9604hGH Fragment 176-191

    Growth hormone fragment studied for weight management. Not licensed in the UK; its largest human trial showed no significant weight-loss benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • GHRP-2Pralmorelin

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK; Japan licenses it only as a diagnostic test. No trial shows a health benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • GHRP-6Growth hormone-releasing…

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. Human studies are short hormone-response and diagnostic work; no trial shows a health benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK

Compare CJC-1295 with Tesamorelin

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.